26-Jul-2024
Trading Halt
24-Jul-2024
Mernova Trading Update
23-Jul-2024
Cleansing Statement
23-Jul-2024
Application for quotation of securities - ME1
23-Jul-2024
Cleansing Statement
23-Jul-2024
$12m Proposed Cash Asset Sale to Strengthen Balance Sheet
22-Jul-2024
Application for quotation of securities - ME1
11-Jul-2024
Notification of cessation of securities - ME1
8-Jul-2024
Secondary Trading Notice
8-Jul-2024
Application for quotation of securities - ME1
8-Jul-2024
Application for quotation of securities - ME1
5-Jul-2024
Update - Application for quotation of securities - ME1
3-Jul-2024
Application for quotation of securities - ME1
3-Jul-2024
Trading Update
3-Jul-2024
Secondary Trading Notice
28-Jun-2024
Mernova Trading Update
27-Jun-2024
Disclosure Document
27-Jun-2024
Application for quotation of securities - ME1
26-Jun-2024
Notification of cessation of securities - ME1
25-Jun-2024
Cleansing Statement
25-Jun-2024
Application for quotation of securities - ME1
24-Jun-2024
Cleansing Statement
24-Jun-2024
Application for quotation of securities - ME1
19-Jun-2024
Cleansing Statement
19-Jun-2024
Application for quotation of securities - ME1
19-Jun-2024
ME1 Corporate Update Including Appendix B
19-Jun-2024
Proposed issue of securities - ME1
19-Jun-2024
ME1 - Corporate Update
19-Jun-2024
Cleansing Statement
19-Jun-2024
Application for quotation of securities - ME1
14-Jun-2024
Proposed issue of securities - ME1
12-Jun-2024
Completion of Security Consolidation
11-Jun-2024
Notification of cessation of securities - ME1
7-Jun-2024
Notification of cessation of securities - ME1
5-Jun-2024
Extension of Secured Notes
3-Jun-2024
Secondary Trading Notice
3-Jun-2024
Application for quotation of securities - ME1
31-May-2024
Secondary Trading Notice
31-May-2024
Application for quotation of securities - ME1
31-May-2024
Results of Annual General Meeting
27-May-2024
Response to ASX Query
27-May-2024
Mernova Trading Update
23-May-2024
Secondary Trading Notice
23-May-2024
Application for quotation of securities - ME1
23-May-2024
Application for quotation of securities - ME1
9-May-2024
Trading Update
3-May-2024
Secondary Trading Notice
3-May-2024
Application for quotation of securities - ME1
2-May-2024
Proposed issue of securities - ME1
2-May-2024
Consolidation/Split - ME1
2-May-2024
Notice of Annual General Meeting/Proxy Form
30-Apr-2024
Final Director's Interest Notice
30-Apr-2024
Proposed issue of securities - ME1
30-Apr-2024
Appointment of Tim Tian as Group CFO
30-Apr-2024
Quarterly Activities/Appendix 4C Cash Flow Report
30-Apr-2024
Board Change
22-Apr-2024
Update - Proposed issue of securities - ME1
22-Apr-2024
Secondary Trading Notice
22-Apr-2024
Application for quotation of securities - ME1
19-Apr-2024
Proposed issue of securities - ME1
19-Apr-2024
Corporate Update
19-Apr-2024
Response to ASX Aware Letter
16-Apr-2024
ME1 Q1 FY24 Revenue
9-Apr-2024
Proposed issue of securities - ME1
9-Apr-2024
Application for quotation of securities - ME1
9-Apr-2024
Health House Australia and Corporate Update
8-Apr-2024
Extension of Cleansing Offer Closing Date
2-Apr-2024
Proposed issue of securities - ME1
2-Apr-2024
Application for quotation of securities - ME1
2-Apr-2024
Mernova Trading Update
28-Mar-2024
Annual Report to shareholders
28-Mar-2024
Appendix 4G and Corporate Governance Statement
27-Mar-2024
ME1 Q1 FY24 Revenue Update
26-Mar-2024
Application for quotation of securities - ME1
26-Mar-2024
Application for quotation of securities - ME1
26-Mar-2024
Application for quotation of securities - ME1
25-Mar-2024
Notification regarding unquoted securities - ME1
25-Mar-2024
Application for quotation of securities - ME1
25-Mar-2024
Disclosure Document
11-Mar-2024
Response to ASX Query
29-Feb-2024
FY 2023 Results
29-Feb-2024
Preliminary Final Report
28-Feb-2024
Secondary Trading Notice
28-Feb-2024
Application for quotation of securities - ME1
27-Feb-2024
Secondary Trading Notice
27-Feb-2024
Application for quotation of securities - ME1
21-Feb-2024
Proposed issue of securities - ME1
21-Feb-2024
Proposed issue of securities - ME1
21-Feb-2024
Capital Raising & Corporate Update
21-Feb-2024
Proposed issue of securities - ME1
21-Feb-2024
Proposed issue of securities - ME1
19-Feb-2024
Trading Halt
12-Feb-2024
Mernova Continues Strong Performance in Q1 FY24
7-Feb-2024
HHI Revenue Update
5-Feb-2024
Mernova Revenue Update
2-Feb-2024
Appendix 2A x2 and Secondary Trading Notice
2-Feb-2024
Completion of Share Consolidation
31-Jan-2024
Quarterly Activities/Appendix 4C Cash Flow Report
23-Jan-2024
Results of Meeting
19-Jan-2024
Change of Director's Interest Notice x 2
19-Jan-2024
Notification of cessation of securities - ME1
16-Jan-2024
Mernova Revenue Update and Placement
16-Jan-2024
Application for quotation of securities - ME1
16-Jan-2024
Proposed issue of securities - ME1
27-Dec-2023
Notification of cessation of securities - ME1
22-Dec-2023
Consolidation/Split - ME1
22-Dec-2023
Notice of General Meeting/Proxy Form
22-Dec-2023
Proposed issue of securities - ME1
22-Dec-2023
Proposed issue of securities - ME1
22-Dec-2023
Proposed issue of securities - ME1
22-Dec-2023
Proposed issue of securities - ME1
22-Dec-2023
Company Secretary Appointment/Resignation
14-Dec-2023
Response to Aware Query
13-Dec-2023
Group Revenue Update
8-Dec-2023
Change of Director's Interest Notice
8-Dec-2023
Change in substantial holding
7-Dec-2023
Cleansing Notice
7-Dec-2023
Application for quotation of securities - ME1
7-Dec-2023
Corporate Update
7-Dec-2023
Proposed issue of securities - ME1
7-Dec-2023
Proposed issue of securities - ME1
29-Nov-2023
Application for quotation of securities - ME1
27-Nov-2023
Application for quotation of securities - ME1
22-Nov-2023
Extension of Prospectus Offer Closing Date
22-Nov-2023
Change of Auditor
21-Nov-2023
Application for quotation of securities - ME1
20-Nov-2023
Change of Director's Interest Notice x 4
20-Nov-2023
Application for quotation of securities - ME1
17-Nov-2023
Application for quotation of securities - ME1
17-Nov-2023
Application for quotation of securities - ME1
17-Nov-2023
Application for quotation of securities - ME1
17-Nov-2023
Application for quotation of securities - ME1
16-Nov-2023
Application for quotation of securities - ME1
16-Nov-2023
Notification regarding unquoted securities - ME1
16-Nov-2023
Application for quotation of securities - ME1
16-Nov-2023
Application for quotation of securities - ME1
15-Nov-2023
Change of Director's Interest Notice
15-Nov-2023
Health House Australia Revenue Update
13-Nov-2023
Top 20 Holders
13-Nov-2023
Distribution Schedule
13-Nov-2023
Application for quotation of securities - ME1
13-Nov-2023
Cancel - Proposed issue of securities - ME1
13-Nov-2023
Cancel - Proposed issue of securities - ME1
13-Nov-2023
Proposed issue of securities - ME1
13-Nov-2023
Proposed issue of securities - ME1
13-Nov-2023
Capital Raising Re-Price & Prospectus Offers Extension
10-Nov-2023
Application for quotation of securities - ME1
10-Nov-2023
Notification regarding unquoted securities - ME1
10-Nov-2023
Notification regarding unquoted securities - ME1
9-Nov-2023
Trading Halt
8-Nov-2023
Update - Proposed issue of securities - ME1
6-Nov-2023
Proposed issue of securities - ME1
6-Nov-2023
Supplementary Prospectus - Bonus Options
3-Nov-2023
Change of Director's Interest Notice x 4
3-Nov-2023
Change in substantial holding
3-Nov-2023
Ceasing to be a substantial holder
2-Nov-2023
Application for quotation of securities - ME1
2-Nov-2023
Becoming a substantial holder
2-Nov-2023
Mernova Revenue Update
31-Oct-2023
Quarterly Activities/Appendix 4C Cash Flow Report
31-Oct-2023
Update - Proposed issue of securities - ME1
31-Oct-2023
Prospectus - Bonus Options
30-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Proposed issue of securities - ME1
27-Oct-2023
Proposed issue of securities - ME1
27-Oct-2023
Cleansing Notice
27-Oct-2023
Notification regarding unquoted securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
27-Oct-2023
Application for quotation of securities - ME1
26-Oct-2023
Change of Director's Interest Notice
26-Oct-2023
Notification of cessation of securities - ME1
26-Oct-2023
Cleansing Notice
26-Oct-2023
Application for quotation of securities - ME1
26-Oct-2023
Application for quotation of securities - ME1
26-Oct-2023
Proposed issue of securities - ME1
26-Oct-2023
Capital Raising & Corporate Update
26-Oct-2023
Proposed issue of securities - ME1
26-Oct-2023
Proposed issue of securities - ME1
26-Oct-2023
Proposed issue of securities - ME1
24-Oct-2023
Application for quotation of securities - ME1
24-Oct-2023
Proposed issue of securities - ME1
24-Oct-2023
Application for quotation of securities - ME1
24-Oct-2023
Trading Halt
23-Oct-2023
Proposed issue of securities - ME1
23-Oct-2023
Bonus Issue of Options and Other Corporate Updates
20-Oct-2023
Mernova Q4 Revenue and New Purchase Orders Update
18-Oct-2023
Application for quotation of securities - ME1
18-Oct-2023
Application for quotation of securities - ME1
18-Oct-2023
Application for quotation of securities - ME1
18-Oct-2023
Application for quotation of securities - ME1
18-Oct-2023
Results of General Meeting
18-Oct-2023
Melodiol Group Q3 Revenue Update
16-Oct-2023
HHI Australian Operations Results Update
12-Oct-2023
Halucenex Phase II Clinical Trial Update
9-Oct-2023
Mernova Q3 Revenue Update
25-Sep-2023
Mernova New Purchase Orders Update
12-Sep-2023
Proposed issue of securities - ME1
12-Sep-2023
Notice of General Meeting/Proxy Form
11-Sep-2023
Mernova Maiden Alberta PO and Revenue Update
5-Sep-2023
Proposed issue of securities - ME1
4-Sep-2023
Cleansing Notice
4-Sep-2023
Debt Restructure Update
4-Sep-2023
Application for quotation of securities - ME1
4-Sep-2023
ImpACTIVE Sponsorship Deal & Promising Regulatory Shifts
31-Aug-2023
Half Year Results Commentary
31-Aug-2023
Half Yearly Report and Accounts
28-Aug-2023
Application for quotation of securities - ME1
21-Aug-2023
Mernova Q3 Sales Update
18-Aug-2023
Restricted Securities to be Released from Escrow
14-Aug-2023
Cleansing Notice
14-Aug-2023
Application for quotation of securities - ME1
11-Aug-2023
Response to ASX Aware Query
9-Aug-2023
Cleansing Notice
8-Aug-2023
Application for quotation of securities - ME1
8-Aug-2023
Application for quotation of securities - ME1
8-Aug-2023
Proposed issue of securities - ME1
8-Aug-2023
Proposed issue of securities - ME1
8-Aug-2023
Proposed issue of securities - ME1
8-Aug-2023
Capital Raising and Debt to Equity Conversions
4-Aug-2023
Trading Halt
2-Aug-2023
LOI for Sale of Sierra Sage and Halucenex to Panacea
31-Jul-2023
Cancel - Proposed issue of securities - ME1
31-Jul-2023
Quarterly Activities/Appendix 4C Cash Flow Report
26-Jul-2023
Mernova Makes Strong Progress on EU GMP Licence Process
24-Jul-2023
Subsidiary HHI Delivers Strong Revenue & EBITDA in H1 2023
21-Jul-2023
Notification of cessation of securities - ME1
19-Jul-2023
Strong Start to Q3 CY2023 with $1.6m in New Revenue & POs
13-Jul-2023
Record Revenue Quarter With Group Sales Up 105%
10-Jul-2023
Mernova Delivers Record Half Yearly Revenues
7-Jul-2023
Notification regarding unquoted securities - ME1
7-Jul-2023
Application for quotation of securities - ME1
6-Jul-2023
Change of Director's Interest Notice x2
3-Jul-2023
Health House International Revenue Update
30-Jun-2023
Appendix 3G
30-Jun-2023
Appendix 2A
26-Jun-2023
Appendix 2A
26-Jun-2023
Appendix 3H
21-Jun-2023
Appendix 2A
21-Jun-2023
Change in substantial holding
19-Jun-2023
Appendix 3B - Amendment
19-Jun-2023
Appendix 3B
15-Jun-2023
Appendix 3G
15-Jun-2023
Appendix 2A
15-Jun-2023
Disclosure Document
14-Jun-2023
Appendix 3B
14-Jun-2023
Appendix 2A
14-Jun-2023
Debt Conversions and Extensions
13-Jun-2023
Change of Company Name and ASX Code
9-Jun-2023
Notification regarding unquoted securities - CPH
9-Jun-2023
LOI to Import MDMA & Psilocybin Treatments to Australia
9-Jun-2023
LOI to Import MDMA & Psilocybin Treatments to Australia
8-Jun-2023
Application for quotation of securities - CPH
6-Jun-2023
Notification of cessation of securities - CPH
5-Jun-2023
Mernova Appoints CannDelta to Map EU GMP Export Process
2-Jun-2023
Notification regarding unquoted securities - CPH
2-Jun-2023
Cleansing Notice - Convertible Notes
31-May-2023
Results of Meeting
24-May-2023
SBC Facility - Second Purchase & Amortisation Payments
24-May-2023
Application for quotation of securities - CPH
24-May-2023
Proposed issue of securities - CPH
24-May-2023
Application for quotation of securities - CPH
24-May-2023
Cleansing Notice
24-May-2023
Application for quotation of securities - CPH
24-May-2023
Notification of cessation of securities - CPH
24-May-2023
Application for quotation of securities - CPH
24-May-2023
Application for quotation of securities - CPH
22-May-2023
Mernova Q2 Sales Update
19-May-2023
Proposed issue of securities - CPH
19-May-2023
Proposed issue of securities - CPH
19-May-2023
Proposed issue of securities - CPH
19-May-2023
Capital Raising & Debt Repayment
17-May-2023
Trading Halt
16-May-2023
Notification regarding unquoted securities - CPH
16-May-2023
Response to Financial Condition Query
16-May-2023
Application for quotation of securities - CPH
15-May-2023
Results of Meeting
15-May-2023
Creso Pharma Expands Asia Market Footprint
10-May-2023
Response to ASX Price Query
10-May-2023
Sierra Sage Herbs LLC Update
5-May-2023
Halucenex Phase II Clinical Trial Update
2-May-2023
Application for quotation of securities - CPH
1-May-2023
Notice of Annual General Meeting/Proxy Form
1-May-2023
Mernova - Eighth Province Entry & $553k in New POs
28-Apr-2023
Quarterly Activities/Appendix 4C Cash Flow Report
19-Apr-2023
Mernova - Q1 Cashflow Positive With Record Revenues
14-Apr-2023
ASX Listing Rule 3.13.1 Notice Regarding AGM
14-Apr-2023
Notice of General Meeting/Proxy Form
6-Apr-2023
February Placement Update & Additional Information
31-Mar-2023
Appendix 4G and Corporate Governance Statement
31-Mar-2023
Annual Report to Shareholders
29-Mar-2023
Notification of cessation of securities - CPH
15-Mar-2023
Notification regarding unquoted securities - CPH
13-Mar-2023
Resolution of Historical ASX Listing Rule Breach
13-Mar-2023
Censure of Creso Pharma Limited
13-Mar-2023
Cleansing Notice - Convertible Notes
7-Mar-2023
Application for quotation of securities - CPH
6-Mar-2023
Cancel - Proposed issue of securities - CPH
6-Mar-2023
Proposed issue of securities - CPH
6-Mar-2023
Proposed issue of securities - CPH
6-Mar-2023
Proposed issue of securities - CPH
6-Mar-2023
Proposed issue of securities - CPH
6-Mar-2023
$2.5M Con Note Issue, Rollover & Extinguishment of Debt
28-Feb-2023
Creso Reports Strong Financial Performance in FY22
28-Feb-2023
Preliminary Final Report
24-Feb-2023
Secondary Trading Notice
24-Feb-2023
Application for quotation of securities - CPH
17-Feb-2023
Proposed issue of securities - CPH
17-Feb-2023
CPH Secures Firm Commitments to Raise $2m
15-Feb-2023
Notification of cessation of securities - CPH
15-Feb-2023
Trading Halt
14-Feb-2023
Restricted Securities to be Released from Escrow
9-Feb-2023
Creso reports strong progress across business units
7-Feb-2023
Halucenex to pursue AUS entry after landmark TGA decision
3-Feb-2023
Change of Director's Interest Notice x 2
2-Feb-2023
Distribution Schedule
2-Feb-2023
Top 20 securityholders
2-Feb-2023
Appendix 2A
31-Jan-2023
Application for quotation of securities - CPH
31-Jan-2023
Quarterly Activities/Appendix 4C Cash Flow Report
27-Jan-2023
Notification regarding unquoted securities - CPH
27-Jan-2023
Notification regarding unquoted securities - CPH
27-Jan-2023
Proposed issue of securities - CPH
27-Jan-2023
Disclosure Document
27-Jan-2023
Proposed issue of securities - CPH
27-Jan-2023
Proposed issue of securities - CPH
27-Jan-2023
La Plata Debt Restructure & Abby and Finn LOI
27-Jan-2023
Application for quotation of securities - CPH
27-Jan-2023
Proposed issue of securities - CPH
27-Jan-2023
Application for quotation of securities - CPH
25-Jan-2023
Trading Halt
25-Jan-2023
Pause in Trading
24-Jan-2023
Mernova - New Province Entry & Largest Ever PO
17-Jan-2023
Application for quotation of securities - CPH
17-Jan-2023
Change of Director's Interest Notice x3
12-Jan-2023
Notification regarding unquoted securities - CPH
12-Jan-2023
Notification regarding unquoted securities - CPH
12-Jan-2023
Notification of cessation of securities - CPH
11-Jan-2023
Mernova wins seven new product listings in Nova Scotia
10-Jan-2023
Secondary Trading Notice
10-Jan-2023
Application for quotation of securities - CPH
10-Jan-2023
Application for quotation of securities - CPH
10-Jan-2023
Application for quotation of securities - CPH
10-Jan-2023
Proposed issue of securities - CPH
10-Jan-2023
ZLD: Receipt of Creso Shares and Settlement of HHI loan
9-Jan-2023
Creso raises $500k in convertible notes
9-Jan-2023
Application for quotation of securities - CPH
9-Jan-2023
Notification regarding unquoted securities - CPH
29-Dec-2022
Results of Meeting
22-Dec-2022
Top 20 Holder Report
20-Dec-2022
Notice of Expiry of Listed Options
15-Dec-2022
Proposed issue of securities - CPH
15-Dec-2022
Secured Convertible Notes Offer Update
12-Dec-2022
Notification regarding unquoted securities - CPH
8-Dec-2022
Extension of March Options Offer under Prospectus
7-Dec-2022
Halucenex administers first dose
5-Dec-2022
Response to ASX Query
2-Dec-2022
Notification regarding unquoted securities - CPH
2-Dec-2022
Application for quotation of securities - CPH
2-Dec-2022
Application for quotation of securities - CPH
2-Dec-2022
Initial Director's Interest Notice
2-Dec-2022
Final Director's Interest Notice
1-Dec-2022
Board Changes
28-Nov-2022
Proposed issue of securities - CPH
28-Nov-2022
Prospectus
25-Nov-2022
Notice of General Meeting/Proxy Form
23-Nov-2022
HHI Update & Product Registration Achieved in South Korea
22-Nov-2022
Creso is no longer the subject of ASIC Investigation
22-Nov-2022
Pause in trading
21-Nov-2022
Proposed issue of securities - CPH
21-Nov-2022
Proposed issue of securities - CPH
21-Nov-2022
ZLD: Partial Receipt and variation of Health House loan
18-Nov-2022
Mernova Update
17-Nov-2022
Replacement of Chairman
9-Nov-2022
Sierra Sage Herbs LLC Expands into Canada
3-Nov-2022
Secondary Trading Notice
3-Nov-2022
Application for quotation of securities - CPH
3-Nov-2022
Mernova Secures Cannabis 2.0 Sales License
1-Nov-2022
Quarterly Activities/Appendix 4C Cash Flow Report
1-Nov-2022
Proposed issue of securities - CPH
1-Nov-2022
CPH Secures Commitments to Raise up to $7.6m
28-Oct-2022
Trading Halt
25-Oct-2022
Change of Director's Interest Notice
25-Oct-2022
Notice of Breach of ASX Listing Rule 10.11
19-Oct-2022
Application for quotation of securities - CPH
17-Oct-2022
Final Director's Interest Notice
14-Oct-2022
Initial Director's Interest Notice x2
13-Oct-2022
Sierra Sage enters into agreement with accelerate360
10-Oct-2022
Melodiol Global Health - Rebranding Strategy
10-Oct-2022
Board Transition & Change of Company Name
10-Oct-2022
Proposed issue of securities - CPH
6-Oct-2022
Halucenex completes clinical trial patient recruitment
4-Oct-2022
Mernova Update
29-Sep-2022
Mernova Update
20-Sep-2022
Notification of cessation of securities - CPH
14-Sep-2022
Halucenex Update
6-Sep-2022
Change of Director's Interest Notice
6-Sep-2022
Becoming a substantial holder
2-Sep-2022
Sierra Sage secures US$214,000 purchase order from Walmart
31-Aug-2022
Half Yearly Report and Accounts
31-Aug-2022
Secondary Trading Notice
29-Aug-2022
Notification regarding unquoted securities - CPH
29-Aug-2022
Application for quotation of securities - CPH
29-Aug-2022
Creso Pharma completes Sierra Sage Herbs LLC Acquisition
29-Aug-2022
Application for quotation of securities - CPH
22-Aug-2022
Halucenex Update
15-Aug-2022
Secondary Trading Notice
15-Aug-2022
Application for quotation of securities - CPH
15-Aug-2022
Proposed issue of securities - CPH
15-Aug-2022
impACTIVE appoints New Brand Ambassador, Kolby Tullier
9-Aug-2022
Results of Meeting
8-Aug-2022
Proposed issue of securities - CPH
8-Aug-2022
Application for quotation of securities - CPH
8-Aug-2022
Mernova Update
4-Aug-2022
Proposed issue of securities - CPH
4-Aug-2022
Reinstatement to Official Quotation
4-Aug-2022
Capital Raising & Q2 22 Quarterly Activities Report Updates
2-Aug-2022
Extension to Voluntary Suspension
1-Aug-2022
Quarterly Activities/Appendix 4C Cash Flow Report
29-Jul-2022
HHI: Creso makes non-binding ind.proposal to acquire HHI
29-Jul-2022
Execution of non-binding term sheet to acquire Health House
29-Jul-2022
Suspension from Quotation
28-Jul-2022
Change of Director's Interest Notice
28-Jul-2022
Notification of cessation of securities - CPH
27-Jul-2022
Trading Halt
25-Jul-2022
SSH secures Private Label Manufacturing Agreement
21-Jul-2022
Mernova Update
18-Jul-2022
Halucenex Update
14-Jul-2022
Proposed issue of securities - CPH
14-Jul-2022
Application for quotation of securities - CPH
14-Jul-2022
Creso Pharma ImpACTIVE appoints three new brand ambassadors
12-Jul-2022
LOI secured with Providence Animal Health Korea Ltd
11-Jul-2022
Notice of General Meeting/Proxy Form
7-Jul-2022
HoA secured to launch SSH products in Singapore
30-Jun-2022
Heads of Agreement secured to launch SSH products in Taiwan
28-Jun-2022
Mernova Update
15-Jun-2022
Application for quotation of securities - CPH
15-Jun-2022
Application for quotation of securities - CPH
15-Jun-2022
Notification of cessation of securities - CPH
14-Jun-2022
Mernova Update
31-May-2022
Amended Constitution
31-May-2022
Results of Meeting
30-May-2022
Halucenex Enters into Supply Agreement with Optimi Health
23-May-2022
Creso Secures Heads of Agreement with Dr Pickles
10-May-2022
Halucenex Secures Import Permit from Health Canada
3-May-2022
Investor Presentation
29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report
28-Apr-2022
Notice of Annual General Meeting/Proxy Form
12-Apr-2022
ASX Listing Rule 3.13.1 Notice Regarding AGM
7-Apr-2022
Sierra Sage Increases to 110,000 Points of Sale
5-Apr-2022
US ROADSHOW - COMPANY PRESENTATION
5-Apr-2022
Notification regarding unquoted securities - CPH
5-Apr-2022
Application for quotation of securities - CPH
4-Apr-2022
US House of Representatives Passes Cannabis Act
1-Apr-2022
Proposed issue of securities - CPH
1-Apr-2022
Notification of cessation of securities - CPH
1-Apr-2022
LOI Secured with Laboratorios Brouwer for LATAM Market
28-Mar-2022
Halucenex Update
21-Mar-2022
Mernova reaches significant market share milestone
16-Mar-2022
Sierra Sage to unlock US product sales and manufacturing
4-Mar-2022
Secondary Trading Notice
2-Mar-2022
Notification of cessation of securities - CPH
2-Mar-2022
Application for quotation of securities - CPH
28-Feb-2022
Appendix 4G and Corporate Governance Statement
28-Feb-2022
Appendix 4E and Annual Report to Shareholders
28-Feb-2022
Halucenex secures Clinical Trial Authorisation
25-Feb-2022
Reinstatement to Official Quotation
25-Feb-2022
Proposed issue of securities - CPH
25-Feb-2022
Creso Pharma secures commitments to raise $5m
24-Feb-2022
Suspension From Official Quotation
22-Feb-2022
Trading Halt
21-Feb-2022
Mernova Operational Update
15-Feb-2022
Update on Acquisition of Sierra Sage Herbs
11-Feb-2022
Creso Pharma to Develop New Hemp-Based Lozenge Product
8-Feb-2022
Halucenex Update
3-Feb-2022
Proposed issue of securities - CPH
3-Feb-2022
Investor Presentation - Sierra Sage Acquisition
3-Feb-2022
Creso to enter US CBD Market through Sierra Sage Acquisition
31-Jan-2022
Quarterly Activities/Appendix 4C Cash Flow Report
28-Jan-2022
Application for quotation of securities - CPH
28-Jan-2022
Application for quotation of securities - CPH
25-Jan-2022
Halucenex Lodges Clinical Trial Authorisation
24-Jan-2022
Initial Director's Interest Notice x3
24-Jan-2022
Executive Director Remuneration
17-Jan-2022
Proposed issue of securities - CPH
17-Jan-2022
Creso Pharma Announces Three New Board Appointments
11-Jan-2022
Halucenex Update
6-Jan-2022
Release of Shares from Voluntary Escrow
21-Dec-2021
Application for quotation of securities - CPH
9-Dec-2021
Conversion of Performance Shares
9-Dec-2021
Application for quotation of securities - CPH
8-Dec-2021
Application for quotation of securities - CPH
7-Dec-2021
Mernova on track for quarter-on-quarter revenue growth
2-Dec-2021
Halucenex Awarded Dealer's License Amendment
30-Nov-2021
Trading Halt
25-Nov-2021
Update on Price and Volume Query Response
23-Nov-2021
Trading Halt
23-Nov-2021
Pause in Trading
17-Nov-2021
Application for quotation of securities - CPH
17-Nov-2021
Notification of cessation of securities - CPH
16-Nov-2021
Response to ASX Price and Volume Query
16-Nov-2021
Trading Halt
16-Nov-2021
Pause in Trading
15-Nov-2021
Creso Pharma Completes Integration of ImpACTIVE Assets
11-Nov-2021
Creso Pharma Anticipates Increasing Q4 2021 Swiss Revenue
9-Nov-2021
Dr Brian Walker Resigns as Strategic Consultant
8-Nov-2021
Change of Director's Interest Notice x 3
8-Nov-2021
Halucenex Receives Positive USP 61 and USP 62 Results
5-Nov-2021
Notification regarding unquoted securities - CPH
4-Nov-2021
Proposed issue of securities - CPH
4-Nov-2021
Appointment of Hon. Dr Brian Walker as Strategic Advisor
2-Nov-2021
Top 20 Holders
2-Nov-2021
Distribution Schedule
2-Nov-2021
Application for quotation of securities - CPH
1-Nov-2021
Creso Pharma to Enter Swiss Medicinal Cannabis Market
29-Oct-2021
Quarterly Activities/Appendix 4C Cash Flow Report
27-Oct-2021
Application for quotation of securities - CPH
26-Oct-2021
Secondary Trading Notice
26-Oct-2021
Proposed issue of securities - CPH
26-Oct-2021
Prospectus - Bonus Options
25-Oct-2021
Creso Completes Acquisition of the Assets of ImpACTIVE
25-Oct-2021
Notification regarding unquoted securities - CPH
25-Oct-2021
Application for quotation of securities - CPH
25-Oct-2021
Proposed issue of securities - CPH
25-Oct-2021
Proposed issue of securities - CPH
25-Oct-2021
Creso Pharma to Acquire ImpACTIVE Holdings Ltd Assets
11-Oct-2021
Mernova Completes THC Content Testing on New Strains
6-Oct-2021
Halucenex Update
5-Oct-2021
Mernova Secures over A$800,000 in New Purchase Orders
5-Oct-2021
Pause in Trading
20-Sep-2021
Halucenex Secures Research Agreement with Acadia University
20-Sep-2021
Pause in Trading
17-Sep-2021
Creso Pharma Launches New E-commerce Channels
13-Sep-2021
Secondary Trading Notice
13-Sep-2021
Creso Secures New Purchase Orders for Human Health Products
9-Sep-2021
Investor Presentation
6-Sep-2021
Notification regarding unquoted securities - CPH
6-Sep-2021
Proposed issue of securities - CPH
6-Sep-2021
Application for quotation of securities - CPH
6-Sep-2021
Creso Pharma Strengthens Management & Executive Team
31-Aug-2021
Half Yearly Report and Accounts
31-Aug-2021
Notification regarding unquoted securities - CPH
31-Aug-2021
NASDAQ Listing & RLH Merger Update
23-Aug-2021
Notification of cessation of securities - CPH
23-Aug-2021
Halucenex Commissions Extraction Unit
16-Aug-2021
Halucenex Awarded Dealer's License from Health Canada
12-Aug-2021
Trading Halt
12-Aug-2021
Pause in Trading
11-Aug-2021
Mernova secures medicinal cannabis sales licence & new POs
4-Aug-2021
Halucenex Continues to Make Progress ahead of Clinical Trial
2-Aug-2021
Quarterly Update & Appendix 4C
30-Jul-2021
Exercise of Options
30-Jul-2021
Application for quotation of securities - CPH
30-Jul-2021
Notification of cessation of securities - CPH
30-Jul-2021
Mernova to Introduce Fourteen New Strains
23-Jul-2021
Halucenex enters into a MOU with Landing Strong
20-Jul-2021
Bruce Linton Confirms Position
16-Jul-2021
CPH Launches cannaDOL through Multiple Distribution Channels
15-Jul-2021
Change of Director's Interest Notice x 3
15-Jul-2021
Creso Pharma Completes the Acquisition of Halucenex
15-Jul-2021
Appendix 2A
15-Jul-2021
Appendix 3G
15-Jul-2021
Secondary Trading Notice
13-Jul-2021
Notification of cessation of securities - CPH
9-Jul-2021
Application for quotation of securities - CPH
9-Jul-2021
Creso Completes Import Procedure in Uruguay for anibidiol
7-Jul-2021
Change in substantial holding
7-Jul-2021
Change of Director's Interest Notice
6-Jul-2021
Creso Secures First Purchase Order from Red Light Holland
2-Jul-2021
Halucenex Update
1-Jul-2021
Reinstatement to Official Quotation
1-Jul-2021
Creso's Second Consecutive Quarter of Record Revenue Growth
29-Jun-2021
Suspension from Official Quotation
25-Jun-2021
Trading Halt
24-Jun-2021
Results of Meeting
18-Jun-2021
Investor Presentation
17-Jun-2021
Proposed issue of securities - CPH
17-Jun-2021
Creso Pharma & Red Light Holland to Merge
16-Jun-2021
Trading Halt
11-Jun-2021
Creso Pharma completes US OTC dual listing
8-Jun-2021
Halucenex Expands its Clinical Trials Plans
4-Jun-2021
Distribution Agreement Expanded to Cover 14 Countries
3-Jun-2021
Creso & Halucenex welcome Californian Senate Bill
26-May-2021
Halucenex prepares North American market entry
24-May-2021
Proposed issue of Securities - CPH
24-May-2021
Update - Proposed issue of Securities - CPH
24-May-2021
Update - Proposed issue of Securities - CPH
24-May-2021
Update - Proposed issue of Securities - CPH
21-May-2021
Notice of Annual General Meeting/Proxy Form
21-May-2021
Creso Pharma signs Letter of Intent with Polvet
18-May-2021
Creso Launches New Product
17-May-2021
Mernova Awarded Craft Designation with OCS
14-May-2021
Halucenex Secures Additional Pharmaceutical Grade Psilocybin
12-May-2021
Trading Halt
12-May-2021
Pause in Trading
6-May-2021
Halucenex secures agreement with R&D partner Nucro-Technics
5-May-2021
Appendix 2A
30-Apr-2021
Quarterly Update & Appendix 4C
19-Apr-2021
Halucenex Update
14-Apr-2021
Commercial Agreement with Cannabis Queen, South Africa
12-Apr-2021
ASX Listing Rule 3.13.1 Notice Regarding AGM
12-Apr-2021
Halucenex Update
8-Apr-2021
Mernova secures new purchase orders & launches new products
6-Apr-2021
Creso appoints US executive to lead US entry strategy
1-Apr-2021
Secondary Trading Notice
1-Apr-2021
Appendix 2A
1-Apr-2021
Creso launches three new CBD tea products
31-Mar-2021
Creso continues positive progress with Halucenex
29-Mar-2021
Proposed issue of Securities - CPH
26-Mar-2021
Appendix 2A
26-Mar-2021
Proposed issue of Securities - CPH
26-Mar-2021
Creso Receives Firm Commitments to Raise $18M
24-Mar-2021
Trading Halt
23-Mar-2021
Creso to dual list on US OTC & Halucenex Update
19-Mar-2021
Appendix 2A
19-Mar-2021
New Mernova Purchase Orders & Launch of Pre-Roll Product
17-Mar-2021
Final Director's Interest Notice
17-Mar-2021
Halucenex Clinical Trial & Acquisition Update
15-Mar-2021
Change of Director's Interest Notice
15-Mar-2021
Halucenex Company Presentation
15-Mar-2021
Proposed issue of Securities - CPH
15-Mar-2021
Creso to Acquire Psychedelics Company, Halucenex
9-Mar-2021
Appendix 4G & Corporate Governance Statement
9-Mar-2021
Annual Report to shareholders
9-Mar-2021
Creso Signs North American Sports Distribution Deal
1-Mar-2021
Creso Signs With US Partner
1-Mar-2021
Preliminary Final Report
26-Feb-2021
Appendix 2A
19-Feb-2021
Appendix 2A
17-Feb-2021
New P.O.'s Demonstrate Strong Uptake
15-Feb-2021
CPH enters Pakistan with $2.5m Distribution Deal
12-Feb-2021
Appendix 2A
8-Feb-2021
Creso brings cannaqix sales inhouse to improve margins
5-Feb-2021
Secondary Trading Notice & Appendix 2A
3-Feb-2021
New POs demonstrate patient uptake
1-Feb-2021
CBD Oil legal in Australia - CPH to benefit
29-Jan-2021
Quarterly Update and Appendix 4C
27-Jan-2021
Change of Director's Interest Notice
22-Jan-2021
Appendix 2A
22-Jan-2021
Appendix 2A
21-Jan-2021
Update - Proposed issue of Securities - CPH
21-Jan-2021
Update - Proposed issue of Securities - CPH
21-Jan-2021
Update - Proposed issue of Securities - CPH
21-Jan-2021
Prospectus
19-Jan-2021
Creso secures POs for record start to FY2021
15-Jan-2021
Appendix 2A
12-Jan-2021
CPH secures $320,000 revenue from second PO in South Africa
11-Jan-2021
Appendix 2A
11-Jan-2021
Becoming a substantial holder
11-Jan-2021
Proposed issue of Securities - CPH
8-Jan-2021
Creso readies for US cannabis legislation reform
31-Dec-2020
Change of Director's Interest Notice
24-Dec-2020
Creso to enter the Hash market in Canada
23-Dec-2020
Appendix 2A
23-Dec-2020
Results of Meeting
21-Dec-2020
CPH Receives Regulatory Approval in Uruguay & Initial PO
18-Dec-2020
Appendix 2A
16-Dec-2020
CPH expands foot print in Canada & is now available online
15-Dec-2020
Creso Welcomes TGA Decision to Reschedule CBD
11-Dec-2020
Heads of Agreement to Unlock Australian Market
9-Dec-2020
CPH Enters Canada's Largest Recreational Market
7-Dec-2020
US House of Representatives Bill to Favour Creso in USA
3-Dec-2020
Creso set to benefit from UN decision to reclassify cannabis
2-Dec-2020
Creso Receives New Purchase Orders - EU
30-Nov-2020
EU Ruling to Benefit Creso
26-Nov-2020
Proposed issue of Securities - CPH
26-Nov-2020
TGA Update
23-Nov-2020
Notice of General Meeting/Proxy Form
30-Oct-2020
Quarterly Update and Appendix 4C
27-Oct-2020
Third Purchase Order from Nova Scotia Liquor Corporation
14-Oct-2020
Ceasing to be a substantial holder
14-Oct-2020
Israeli Market Update
13-Oct-2020
Ceasing to be a substantial holder
13-Oct-2020
Cleansing Prospectus
12-Oct-2020
Secured Debt Update
12-Oct-2020
Change of Director's Interest Notice x 2
12-Oct-2020
Appendix 2A
12-Oct-2020
Change in substantial holding
12-Oct-2020
Second Purchase Order from Pharma Dynamics, South Africa
9-Oct-2020
Second Retail PO from Nova Scotia Liquor Corporation
7-Oct-2020
Canopy Growth founder to join Creso
7-Oct-2020
Proposed issue of Securities - CPH
7-Oct-2020
Proposed issue of Securities - CPH
7-Oct-2020
Creso Pharma receives commitments totaling A$8.992m
6-Oct-2020
Becoming a substantial holder
6-Oct-2020
Ceasing to be a substantial holder
5-Oct-2020
Appendix 2A
2-Oct-2020
Results of Meeting
1-Oct-2020
Trading Halt
30-Sep-2020
Appendix 2A
22-Sep-2020
Addendum to Notice of General Meeting
21-Sep-2020
Mernova Receives First Retail Purchase Order From NSLC
10-Sep-2020
Creso welcomes TGA reclassification of CBD
1-Sep-2020
Appendix 2A
1-Sep-2020
Half Yearly Report and Accounts
28-Aug-2020
Proposed issue of Securities - CPH
27-Aug-2020
Notice of General Meeting/Proxy Form
14-Aug-2020
Company Update
12-Aug-2020
Agreement with DHS Business for Entry into Iberic Markets
3-Aug-2020
Appendix 2A
3-Aug-2020
Quarterly Activities Report and Appendix 4C
15-Jul-2020
Ceasing to be a substantial holder
10-Jul-2020
Mernova Receives US$625k Order for Shipment to Israel
3-Jul-2020
Redemption of Performance Shares
1-Jul-2020
Ceasing to be a substantial holder
30-Jun-2020
Ceasing to be a substantial holder
26-Jun-2020
Appendix 2A
26-Jun-2020
Becoming a substantial holder
26-Jun-2020
Proposed issue of Securities - CPH
26-Jun-2020
Mernova Milestone 2 Update
25-Jun-2020
Issue of Unlisted Securities
25-Jun-2020
Prospectus Offer Period Extension
25-Jun-2020
Appendix 2A
24-Jun-2020
Prospectus Offer Period Extension
24-Jun-2020
Appendix 2A
24-Jun-2020
Mernova Operational Update
24-Jun-2020
Cleansing Prospectus
23-Jun-2020
Appendix 2A
23-Jun-2020
Proposed issue of Securities - CPH
16-Jun-2020
Results of Meeting
15-Jun-2020
Ceasing to be a substantial holder
11-Jun-2020
Change in substantial holding
11-Jun-2020
Israeli Cannabis Legislation Update
10-Jun-2020
Update on Mernova Sales License
9-Jun-2020
Change of Director's Interest Notice
9-Jun-2020
Becoming a substantial holder
9-Jun-2020
Successful launch of Creso's Cannamics in South Africa
4-Jun-2020
Appendix 2A
3-Jun-2020
Appendix 2A
3-Jun-2020
Agreement for Entry into Brazilian Retail Market
2-Jun-2020
Proposed issue of Securities - CPH
2-Jun-2020
Cleansing Prospectus
2-Jun-2020
Placement and Corporate Update
2-Jun-2020
Appendix 2A
1-Jun-2020
Creso Pharma Receives Firm Commitments to Raise A$2.137M
1-Jun-2020
Appendix 2A
1-Jun-2020
Proposed issue of Securities - CPH
28-May-2020
Appendix 2A
28-May-2020
Proposed issue of Securities - CPH
28-May-2020
Appendix 2A
27-May-2020
Trading Halt
18-May-2020
Results of Meeting
13-May-2020
Update on Mernova Sales Licence
12-May-2020
Letter to Shareholders Regarding AGM
12-May-2020
Notice of Annual General Meeting/Proxy Form
11-May-2020
Trading Halt
11-May-2020
Pause In Trade
11-May-2020
Mernova Receives Retail Sales License from Health Canada
30-Apr-2020
Quarterly Update and Appendix 4C (Replacement)
30-Apr-2020
Quarterly Update and Appendix 4C
20-Apr-2020
Appendix 2A
20-Apr-2020
Cleansing Prospectus
20-Apr-2020
Proposed issue of Securities - CPH
20-Apr-2020
Proposed issue of Securities - CPH
20-Apr-2020
Proposed issue of Securities - CPH
20-Apr-2020
Proposed issue of Securities - CPH
20-Apr-2020
Funding Update
20-Apr-2020
Israeli JV Update
15-Apr-2020
Notice of General Meeting/Proxy Form
14-Apr-2020
L1 Capital Collateral Purchase Notice & Top-Up Notice
14-Apr-2020
Pause in Trading
14-Apr-2020
Binding LOI to Expand Distribution into Pakistan
8-Apr-2020
ASX Listing Rule 3.13.1 Notice Regarding AGM
7-Apr-2020
Appendix 3G
7-Apr-2020
Creso Completes AUD 200,000 Order of anibidiol to Virbac
2-Apr-2020
Creso Pharma Outlines Response to COVID-19
2-Apr-2020
Pause in Trading
1-Apr-2020
Mernova Receives C$775k Order for First Shipment to Israel
26-Mar-2020
First Shipment of cannaQIX to South Africa For Launch in Q2
24-Mar-2020
Creso Pharma to Launch CBD Hemp Tea
12-Mar-2020
Ceasing to be a substantial holder - Correction
11-Mar-2020
Ceasing to be a substantial holder
11-Mar-2020
Creso Strengthens Mernova Senior Management Team
10-Mar-2020
Trading Halt
10-Mar-2020
Pause in Trading
6-Mar-2020
Becoming a substantial holder
3-Mar-2020
Creso Signs Agreement to Market its Products in Scandinavia
2-Mar-2020
Termination of Israeli Joint Venture
28-Feb-2020
Appendix 4G & Corporate Governance Statement
28-Feb-2020
Preliminary Report & Annual Report to shareholders
19-Feb-2020
Change of Director's Interest Notice
18-Feb-2020
Appendix 2A
18-Feb-2020
Change in substantial holding
14-Feb-2020
Mernova Milestone 2 Achieved
12-Feb-2020
Issue of Unquoted Securities
11-Feb-2020
Proposed issue of Securities - CPH
11-Feb-2020
Appendix 2A
11-Feb-2020
Appendix 2A
11-Feb-2020
Creso to launch hemp product for equines and large animals
11-Feb-2020
Supplementary Prospectus
7-Feb-2020
Prospectus
6-Feb-2020
Technological Breakthrough for Human Health Products
5-Feb-2020
Appendix 2A
5-Feb-2020
Proposed issue of Securities - CPH
5-Feb-2020
Creso Pharma Secures Further Funding
30-Jan-2020
New Constitution
28-Jan-2020
Results of Meeting
28-Jan-2020
Creso exceeds milestone of 2.5m cannaQIX lozenges sold
23-Jan-2020
Change in substantial holding
21-Jan-2020
Re-engagement of Corporate Advisor
21-Jan-2020
Creso exceeds milestone of 3m anibidiol doses sold in Europe
17-Jan-2020
Quarterly Update and Appendix 4C
13-Jan-2020
Addendum to Notice of General Meeting
8-Jan-2020
Release of Securities From Voluntary Escrow
8-Jan-2020
Response to ASX Price Query
31-Dec-2019
Convertible Note Facility Drawdown
23-Dec-2019
Notice of General Meeting/Proxy Form
19-Dec-2019
Change in substantial holding
12-Dec-2019
Release of Securities From Voluntary Escrow
9-Dec-2019
Creso enters the African continent with cannaQIX products
5-Dec-2019
Commencement of sales of cannaQIX 50 in Australia with BHC
3-Dec-2019
Corporate Presentation - December 2019
2-Dec-2019
Appendix 3B
2-Dec-2019
Placement under ASX Listing Rule 7.1A
2-Dec-2019
Appendix 3B
2-Dec-2019
Reinstatement to Official Quotation
2-Dec-2019
Update on Strategy and Plans to Accelerate Global Operations
28-Nov-2019
Appendix 3B
28-Nov-2019
Waiver from ASX Listing Rule 10.1
28-Nov-2019
Disclosure Document - Debt Note Offer & Cleansing Offer
12-Nov-2019
Termination of Scheme Implementation Agreement
11-Nov-2019
Adjournment of Scheme Meetings
8-Nov-2019
Update on Voluntary Suspension
5-Nov-2019
Suspension from Official Quotation
1-Nov-2019
Trading Halt
1-Nov-2019
Pause in Trade
17-Oct-2019
First Shipment of 10% Medicinal CBD Oil in New Zealand
14-Oct-2019
Quarterly Update & Appendix 4C
4-Oct-2019
Scheme Booklet (Replacement)
4-Oct-2019
Scheme Booklet
4-Oct-2019
Reinstatement to Official Quotation
3-Oct-2019
Update on Proposed Acquisition by PharmaCielo
27-Sep-2019
Update on Proposed Acquisition by PharmaCielo
18-Sep-2019
Voluntary Suspension
16-Sep-2019
Trading Halt
16-Sep-2019
Pause in Trading
16-Sep-2019
Creso Granted Processing Licence for its Mernova Facility
4-Sep-2019
Release of Securities From Voluntary Escrow
26-Aug-2019
Half Yearly Report and Accounts
22-Aug-2019
Creso Signs with Pharma Dynamics for cQIX in South Africa
20-Aug-2019
Creso Receives PCLO's First Commercial CBD Export into EU
8-Aug-2019
Additional Information on Medleaf Distribution Agreement
6-Aug-2019
Distribution Agreement with Medleaf NZ for CBD Products
2-Aug-2019
Change of Director's Interest Notice
1-Aug-2019
First Order of cannaQIX50 from Burleigh Heads Cannabis
31-Jul-2019
Cleansing Statement and Appendix 3B
24-Jul-2019
Quarterly Update & Appendix 4C
15-Jul-2019
Change in substantial holding
15-Jul-2019
Change in substantial holding
12-Jul-2019
Cleansing Statement and Appendix 3B
10-Jul-2019
Becoming a substantial holder
8-Jul-2019
Appendix 3Y x 4
3-Jul-2019
Creso Repays Debt in Preparation for Acquisition & App 3B
2-Jul-2019
Creso Begins Revenue Generation from Canadian Cannabis Sales
7-Jun-2019
Creso Pharma To Be Acquired
4-Jun-2019
Release of Securities From Voluntary Escrow
31-May-2019
Results of Meeting
23-May-2019
Creso Harvests First Cannabis Crop in Canada
30-Apr-2019
BHC Distribution Agreement & Australian Import Permit
29-Apr-2019
Quarterly Update & Appendix 4C
29-Apr-2019
Notice of Annual General Meeting/Proxy Form
23-Apr-2019
Brazil Import Licence - Additional Information
18-Apr-2019
Brazil Import Licence Granted For cannaQIX
15-Apr-2019
Creso Pharma Canadian Cultivation Update
11-Apr-2019
Additional Information on Secured Loans
11-Apr-2019
Creso to Raise AUD5.35m via Secured Loans
9-Apr-2019
Trading Halt
5-Apr-2019
Response to ASX Aware Query
2-Apr-2019
Commercial Progress Across Premium Product Categories
27-Mar-2019
Appendix 4G & Corporate Governance Statement
25-Mar-2019
Annual Report to shareholders
6-Mar-2019
Release of Securities From Voluntary Escrow
28-Feb-2019
CEO's Report on Operations & Appendix 4E
18-Feb-2019
Creso Granted License to Cultivate Cannabis
14-Feb-2019
Strategic Collaboration for CBD products with Hempmate Switz
13-Feb-2019
Strategic Collaboration with Burleigh Heads Cannabis
12-Feb-2019
Reinstatement to Official Quotation
12-Feb-2019
Clarification and Reinstatement to Trading
6-Feb-2019
Suspension Update
4-Feb-2019
Suspension from Official Quotation
1-Feb-2019
Cleansing Statement & Appendix 3B
1-Feb-2019
Trading Halt
1-Feb-2019
Pause In Trading
1-Feb-2019
Colombian Partnership and Appointment of Medical Advisor
31-Jan-2019
Quarterly Update & Appendix 4C
31-Jan-2019
Placement Update, Cleansing Statement & Appendix 3B
30-Jan-2019
Creso and CLV Expand the OBMJ Beers to Switzerland
24-Jan-2019
Creso Raises $3 Million in Institutional Placement
22-Jan-2019
Trading Halt
21-Jan-2019
Creso Signs Supply Agreement with TerrAscend Canada
9-Jan-2019
Creso further builds medical cannabis in NZ with Medleaf
7-Jan-2019
Strategic Collaboration in Sri Lanka for Medical Cannabis
2-Jan-2019
Creso builds on Israel's new Med Cannabis export law
20-Dec-2018
Settlement of Kunna Canada Acquisition - incl Appendix 3B
20-Dec-2018
US CBD hemp market opens to Creso
19-Dec-2018
Update on Creso Pharma Canadian growing facility
17-Dec-2018
Secondary Trading Notice & Appendix 3B
17-Dec-2018
Commercialisation of Animal Health Products Commences
4-Dec-2018
Canada TSX-V Roadshow Presentation
3-Dec-2018
Creso Pharma to Dual List on TSX-V Canada
28-Nov-2018
Interview with Creso COO
14-Nov-2018
Exclusive Distribution Agreement for CPH Veterinary Products
1-Nov-2018
Creso to launch its first medical cannabis product in Brazil
31-Oct-2018
Quarterly Activities Report and Appendix 4C
30-Oct-2018
CPH Establishes Edible Cannabis Product R&D Centre
22-Oct-2018
Appendix 3B - Release from Escrow
19-Oct-2018
Change of Company Secretary
18-Oct-2018
Cleansing Statement & Appendix 3B - Exercise of Options
17-Oct-2018
Creso welcomes legalisation of recreational cannabis, Canada
16-Oct-2018
Results of Meeting
11-Oct-2018
Appendix 3B
9-Oct-2018
Old Boy Mary Jane Beer Launch in London, Berlin
8-Oct-2018
Securities to be released from escrow
8-Oct-2018
Licence application accepted & Construction Finance Loan
18-Sep-2018
FNN Interview with Chief Operating Officer
12-Sep-2018
Appendix 3B - Quotation of Options
11-Sep-2018
Appendix 3B - Options Entitlement Issue Shortfall
11-Sep-2018
Update on Colombian Acquisition & Notice of General Meeting
5-Sep-2018
Creso Pharma Lifestyle Portfolio Update
31-Aug-2018
Quotation of Entitlement Issue Options
28-Aug-2018
Half Yearly Report and Accounts
28-Aug-2018
Appendix 3B - Quotation of Options
27-Aug-2018
Appendix 3Y x 4 - Options Entitlement Issue
21-Aug-2018
Appendix 3B
21-Aug-2018
UK commercialisation of cannaQIX with Pharmacare
17-Aug-2018
Entitlement Issue Shortfall Notice
14-Aug-2018
Commercial agreement for cannaQIX in Austria & East Europe
3-Aug-2018
Dispatch of Entitlement Issue Prospectus
2-Aug-2018
Creso to launch cannaQIX in Israel and the Middle East
31-Jul-2018
Quarterly Activities Report & Appendix 4C
30-Jul-2018
Appendix 3Y - Vesting of Performance Rights
27-Jul-2018
Cleansing Statement & Appendix 3B
26-Jul-2018
Entitlement Issue - Letter to Option holders
26-Jul-2018
Entitlement Issue - Letter to Ineligible Shareholders
26-Jul-2018
Entitlement Issue - Letter to Eligible Shareholders
25-Jul-2018
Appendix 3B
25-Jul-2018
Prospectus - Entitlement Issue
25-Jul-2018
Investor Presentation
23-Jul-2018
Appendix 3Y - Vesting of Performance Rights
23-Jul-2018
Conversion of Performance Rights & Appendix 3B
23-Jul-2018
Options Entitlement Issue
23-Jul-2018
Creso to finalise Colombian Acquisition
17-Jul-2018
Creso now trading on the Frankfurt Stock Exchange
16-Jul-2018
Appendix 3B
2-Jul-2018
Creso launches cannaQIX in New Zealand
25-Jun-2018
Creso JV launches infused terpene craft beers and beverages
21-Jun-2018
Creso welcomes decision to legalise Cannabis use in Canada
14-Jun-2018
Creso appoints Chief Operating Officer, Americas
12-Jun-2018
Licence to cultivate Medicinal Cannabis in Colombia granted
31-May-2018
Results of Meeting
31-May-2018
Update on Colombian Acquisition
21-May-2018
Commercial start of cannaQIX in BENELUX with first orders
16-May-2018
Creso expands into Israeli Medical Cannabis
14-May-2018
Trading Halt
2-May-2018
Notice of Annual General Meeting
30-Apr-2018
Quarterly Activities Report & Appendix 4C
30-Apr-2018
Global Expansion of anibidiol
18-Apr-2018
Creso's JV to launch Global Beers and Tonics
16-Apr-2018
Corporate Update
6-Apr-2018
Update on Colombian Acquisition
15-Mar-2018
Creso launches cannaDOL product range
27-Feb-2018
Appendix 4G
27-Feb-2018
Corporate Governance Statement
27-Feb-2018
Annual Report and Appendix 4E
27-Feb-2018
Creso reports first revenues from cannaQIX and anibidiol
19-Feb-2018
Completion of Mernova acquisition
14-Feb-2018
Market Update on Colombian Operations
13-Feb-2018
Mernova Update
12-Feb-2018
Company Update
9-Feb-2018
Trading Halt
1-Feb-2018
Morningstar Quantitative Equity Report
31-Jan-2018
Quarterly Activities Report & Appendix 4C
29-Jan-2018
Investor Presentation
17-Jan-2018
Commercialisation Agreement signed for UK launch of cannaQIX
11-Jan-2018
Launch of JV for cannabis-derived beverage market
5-Jan-2018
CPH Welcomes AU Govt Law
21-Dec-2017
Cleansing Statement and Appendix 3B
21-Dec-2017
Closure of Share Purchase Plan
19-Dec-2017
CommSec Interview
18-Dec-2017
Colombian Medicinal Cannabis Acquisition
14-Dec-2017
Trading Halt
13-Dec-2017
Mernova Construction Update - Canada
11-Dec-2017
Results of Meeting
4-Dec-2017
Creso signs distribution agreement in Switzerland - CannaQIX
1-Dec-2017
Cleansing Statement, Appendix 3B and LR 3.10.5A Disclosure
29-Nov-2017
Share Purchase Plan
29-Nov-2017
Creso signs binding LOI with Baltic Beer & LGC Capital
28-Nov-2017
Cleansing Statement & Appendix 3B - Exercise of Options
28-Nov-2017
Cleansing Statement - SPP
28-Nov-2017
Reinstatement to Official Quotation
28-Nov-2017
Oversubscribed Placement, SPP and Company Update
27-Nov-2017
Suspension from Official Quotation
22-Nov-2017
Trading Halt
22-Nov-2017
Creso enters Australia Pharma Market
20-Nov-2017
China Strategic Commercial Distribution Agreement Signed
15-Nov-2017
Independent Investment Research Report on Creso
14-Nov-2017
Creso launches first animal health product in Switzerland
13-Nov-2017
Creso welcomes Canadian Tax Reform on Cannabis
9-Nov-2017
Notice of General Meeting
9-Nov-2017
Creso Pharma and LGC Capital announce Strategic Alliance
7-Nov-2017
Research Collaboration with University of Wollongong
1-Nov-2017
Cleansing Statement & Appendix 3B
27-Oct-2017
Creso Market Update
25-Oct-2017
Quarterly Activities Report & Appendix 4C
18-Oct-2017
Appendix 3B - Release of securities from escrow
17-Oct-2017
Morningstar releases Independent Research Report on Creso
13-Oct-2017
Cleansing Statement
13-Oct-2017
Appendix 3B
3-Oct-2017
Securities to be released from escrow
28-Sep-2017
Creso completes DD of Mernova - On track for Completion
21-Sep-2017
Change of registered office address
7-Sep-2017
Investor Presentation
28-Aug-2017
Half Yearly Report and Accounts
9-Aug-2017
Market Update
7-Aug-2017
Creso to Launch Animal Health Products in Switzerland
1-Aug-2017
Q and A on Mernova Medicinal Inc Acquisition
1-Aug-2017
FNN Interview with Chairman and COO - Mernova Medicinal
27-Jul-2017
Cleansing Notice
27-Jul-2017
Appendix 3B
27-Jul-2017
Results of General Meeting
27-Jul-2017
Investor Presentation - Mernova Acquisition
27-Jul-2017
Creso expands into Canada with acquisition of Mernova
26-Jul-2017
Trading Halt
24-Jul-2017
Quarterly Activities Report & Appendix 4C
18-Jul-2017
Appendix 3B
28-Jun-2017
Securities due for release from escrow
28-Jun-2017
Investor Presentation - Product Launches
26-Jun-2017
General Meeting Proxy Form
26-Jun-2017
Notice of General Meeting
26-Jun-2017
Appendix 3B - Release of Securities from Escrow
14-Jun-2017
Market Update - Human & Animal Health Product Development
8-Jun-2017
Securities due for Release from Escrow
2-Jun-2017
Investor Presentation - June 2017
1-Jun-2017
Creso first to export medicinal Cannabis from Switzerland
11-May-2017
LOI signed to expand Creso's offering to Australian Market
5-May-2017
Company Update
2-May-2017
CPH successfully imports Australia's first Cannabis shipment
28-Apr-2017
Quarterly Activities Report & Appendix 4C
24-Apr-2017
Asia Investor Roadshow
19-Apr-2017
Appendix 3B - Share Purchase Plan
13-Apr-2017
Becoming a substantial holder
12-Apr-2017
Cleansing Notice
12-Apr-2017
Appendix 3B & Listing Rule 3.10.5A Disclosure
12-Apr-2017
Results of Annual General Meeting
10-Apr-2017
Share Purchase Plan Closes Oversubscribed
5-Apr-2017
Extension of Closing Date for Share Purchase Plan
4-Apr-2017
Creso appoints Chief Operating Officer
3-Apr-2017
Becoming a substantial holder
3-Apr-2017
FNN Interview with Chairman - Medicinal Cannabis Market
31-Mar-2017
Securities due for release from escrow
31-Mar-2017
Ceasing to be a substantial holder
31-Mar-2017
Change of Director's Interest Notice x 5
31-Mar-2017
Cleansing Statement - Placement
31-Mar-2017
Appendix 3B
30-Mar-2017
Response to ASX Aware Letter
28-Mar-2017
Share Purchase Plan
27-Mar-2017
Cleansing Notice - Share Purchase Plan
27-Mar-2017
Oversubscribed Placement to raise $8m and SPP
23-Mar-2017
Trading Halt
22-Mar-2017
Creso Signs Sales & Distribution Agreement in Brazil
20-Mar-2017
Trading Halt
20-Mar-2017
Trading Halt
17-Mar-2017
Independent Investment Research Report
16-Mar-2017
Sales Update
13-Mar-2017
Notice of Annual General Meeting
13-Mar-2017
Australian Roadshow Presentation
8-Mar-2017
FNN Interview with CEO regarding Domaco
7-Mar-2017
Creso Signs Binding LOI with Domaco
3-Mar-2017
Trading Halt
1-Mar-2017
Appointment to Creso's Scientific Advisory Board
28-Feb-2017
Annual Report and Appendix 4E
28-Feb-2017
Appendix 4G
28-Feb-2017
Corporate Governance Statement
27-Feb-2017
Appendix 3B - Release of Securities from Escrow
24-Feb-2017
Granting of Federal Import Licence to Exclusive Facilitator
14-Feb-2017
Progress with Creso's Human Health Product
8-Feb-2017
Release of Escrowed Securities
3-Feb-2017
Australian LOI signed for Import & Sale of Cannabis Products
2-Feb-2017
Reinstatement to Official Quotation
2-Feb-2017
Australian LOI signed for Import & Sale of Cannabis Products
2-Feb-2017
Request for Voluntary Suspension
2-Feb-2017
Suspension from Official Quotation
31-Jan-2017
Trading Halt
30-Jan-2017
Quarterly Activities Report & Appendix 4C
24-Jan-2017
Appendix 3B
19-Jan-2017
Appendix 3B - Release of Securities from Escrow
18-Jan-2017
Creso Secures EU Registration for Animal Health Products
16-Jan-2017
Trading Halt
9-Jan-2017
Release of Escrowed Securities
8-Dec-2016
Revenue Generation continues for Creso's Hemp Products
6-Dec-2016
Appendix 3B
23-Nov-2016
Executive Directors Interview with Finance News Network
17-Nov-2016
LOI with Canadian Medical Cannabis Group for EU Market
14-Nov-2016
Change of Registered Address
14-Nov-2016
Investor Presentation
10-Nov-2016
IPO Prospectus
7-Nov-2016
Creso Secures Binding LOI for Animal Health Products
31-Oct-2016
Quarterly Activities Report & Appendix 4C
31-Oct-2016
Commercial Distribution Agreement to bring First Revenues
27-Oct-2016
Binding LOI for Commercialisation of Nutraceutical Product
26-Oct-2016
Trading Halt
24-Oct-2016
Initial Director's Interest Notice x 5
24-Oct-2016
Becoming a substantial holder
24-Oct-2016
Investor Presentation
21-Oct-2016
FNN Interview with Executive Directors
20-Oct-2016
Creso Commences Trading on the ASX
18-Oct-2016
Performance Rights Plan Terms & Conditions
18-Oct-2016
Terms & Conditions of Securities
18-Oct-2016
Restricted Securities
18-Oct-2016
Confirmations
18-Oct-2016
Hemp Industries accounts
18-Oct-2016
Updated pro-forma balance sheet
18-Oct-2016
Top 20 Holders
18-Oct-2016
Distribution Schedule
18-Oct-2016
Appendix 1A and Information Form & Checklist
18-Oct-2016
Pre-quotation Disclosure
18-Oct-2016
ASX Notice - Admission & Commencement of Official Quotation
18-Oct-2016
Admission to Official Quotation